Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

First-of-its-Kind Setmelanotide Discovered for Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc discovers first-of-its-kind setmelanotide for the treatment of obesity.

Setmelanotide is not indicated for treating patients with suspected obesity due to POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign. It is also not indicated for obesity related with other genetic syndromes and general (polygenic) obesity.

Some of the side effects of caused with the treatment of Setmelanotide include skin pigmentation, depression, prolonged penile erection etc. For every six months monitoring of heart rate and blood pressure should be done as an essential standard clinical practice for patients treated with setmelanotide.

U.S. Food and Drug Administration (FDA) grants Setmelanotide, the breakthrough designation for the treatment of hypothalamic obesity.

Hypothalamic obesity is a rare cause of extreme obesity that damages the hypothalamic region of the brain including MC4R pathway. It also controls physiological functions such as hunger and weight regulation.

Patients with hypothalamic experience quick weight gain, reduction in energy expenditure and increase in hunger during first six to 12 months following tumor resection, and all these factors ultimately leading to severe obesity.

In U.S, currently there are approximately 5,000-10,000 patients suffering with hypothalamic obesity, giving rise to 500 new cases every year.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024